Page 10 - Norgine Annual Report 2017

Looking

Forward

2018 is a year of acceleration for Norgine.
Norgine will continue to focus on maximising
the sales of its existing products and
integrate the Merus Labs International Executive
Inc. business while also pursuing new
opportunities to diversify its revenue base
and to bring transformative products to Team
patients.

In 2018, we anticipate to further launch
®
PLENVU and LYMPHOSEEK through our
®
infrastructure and we are also anticipating
Peter Stein
®
FDA approval of PLENVU .
Chief Executive Officer

Christopher Bath Peter Martin
Chief Financial Officer Chief Operating Officer

Kenneth Scrimgeour Paul Pay
Chief Commercial Officer Chief Business Development Officer

Dr Alastair Benbow Sheila Hopkins
Chief Development and Chief Legal Officer
Medical Officer

Tara Barry Philippe Caroff
Chief Human Resources Officer Chief Manufacturing Officer

9 10